Development of a customed designed oxygenation system combined with novel therapy to treat reperfusion injury following Neurovascular Thrombectomy.

开发定制设计的氧合系统与新疗法相结合，治疗神经血管血栓切除术后的再灌注损伤。

• 批准号: 10057485
• 金额: $ 44.58万
• 依托单位: CERFEFUZE MEDICAL UK LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10057485
• 关键词: Development; customed; designed; oxygenation; system

Reperfusion Injury paradoxical exacerbation of cellular dysfunction and death, post blood flow restoration to previously ischaemic tissues, post mechanical thrombectomy. Blood flow restoration is mandatory to save ischaemic tissues. However, reperfusion could compromise function/viability of range-of-organs such as heart, lung, kidney, gut, skeletal muscle and brain on their own or even cause l multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in substantial life-threatening tissue destruction.Despite of its high occurrence and related mortality/morbidity/healthcare-burden, there is no treatment available to minimise RI post thrombectomy. Body's own repair mechanisms are all that is relied-upon to recover from the ischemic state. Use of therapeutics have failed as the damaging effect of the blood outweighs benefitsCerefuse Medical aims to bring about the next generation in medical device interventions for ischemic stroke. The mechanism of Reperfusion Injury isn't new to science but it is only now, with sufficient revascularisation rates achieved in stroke care that it is possible to bring this life changing therapy to patients.Previous attempts to use therapeutics have failed to reduce reperfusion injury in the brain. A contributing factor for this is likely the presence of toxic ions and free radicals in the tissue from the reintroduction of whole blood to the post ischemic tissue. In simple terms the damaging effect of the blood outweighs the benefits of the therapeutic agent.Cerefuse's disruptive approach aims to reduce tissue function without relying on pharmaceutical agents to have an effect on tissue (though they will be used to modify the salt profile of the blood).Through this project, Cerefuse will* Design/assemble functional prototype device that can successfully modify the blood parameters,* Design and implement an initial animal study to show safety and efficacy in minimising RI occurrence.* Develop _in-vitro_ models to evaluate blood parameters* Prepare regulatory-approvals-strategy* Solidify IP position

再灌注损伤细胞功能障碍和死亡的反常恶化，之前缺血组织的血流恢复后，机械血栓切除术后。血流恢复对于挽救缺血组织是强制性的。然而，再灌注可能会损害一系列器官（例如心脏、肺、肾、肠、骨骼肌和脑）自身的功能/存活力，甚至导致多系统器官衰竭。再灌注损伤是一个多因素的过程，导致严重危及生命的组织破坏。尽管其发生率高，相关死亡率/发病率/医疗保健负担高，但没有治疗方法可以最大限度地减少血栓切除术后的RI。身体自身的修复机制是从缺血状态恢复所依赖的。由于血液的破坏作用超过了益处，治疗方法的使用已经失败。再灌注损伤的机制对科学来说并不新鲜，但直到现在，随着中风护理中实现了足够的血运重建率，才有可能将这种改变生命的疗法带给患者。以前使用治疗方法的尝试未能减少大脑中的再灌注损伤。一个促成因素可能是组织中存在毒性离子和自由基，这些离子和自由基来自于将全血重新引入缺血后组织。简单地说，血液的破坏作用超过了治疗剂的益处。Cerefuse的破坏性方法旨在降低组织功能，而不依赖于药物制剂对组织产生影响（尽管它们将用于修改血液的盐含量）。通过这个项目，Cerefuse将 * 设计/组装功能原型设备，可以成功地修改血液参数，* 设计并实施初步动物研究，以显示最大限度减少RI发生的安全性和有效性。开发体外模型以评价血液参数 * 准备监管批准策略 * 巩固IP地位